This is a multicenter, randomized, double-blind clinical trial to evaluate the efficacy and safety of Chinese herbal compound in improving fatigue symptoms and quality of life in patients with chemotherapy.

In this study, symptomatic indicators and quality of life were used as the main evaluation indicators. Patients with moderate to severe CRF who received dual drug chemotherapy were given traditional Chinese medicine compound and placebo intervention respectively. The data of fatigue symptoms, quality of life, sleep quality, blood routine test, liver and kidney function were observed and compared, so as to verify the traditional Chinese medicine compound prescription in improving the CRF symptoms and quality of life of chemotherapy patients validity.

Inclusion Criteria:

• Malignant tumor patients with pathological diagnosis
• Men and women aged 18-75
• KPS score ≥ 70, expected survival time more than 6 months
• The function of heart, lung, liver and kidney was normal
• Hemoglobin ≥ 8g
• Neuroendocrine function is normal
• BMI ≥ 18.5.
• Cancer pain, VAS score < 3
• Fatigue score ≥ 4
• syndrome differentiation is deficiency of Qi and blood

Exclusion Criteria:

• Brain metastases with Symptomatic
• Mental disease
• Severe infection
• Insomniacs
• Pregnant or lactating women